Source: https://www.malignanttumors.org/jour/article/view/272
Timestamp: 2019-04-26 14:37:16+00:00

Document:
1. Liedtke C., Mazouni C., Hess K. R. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer // J Clin Oncol.– 2008. V. 26.– I. 8.– P. 1275–1281.
2. von Minckwitz G.I., Untch M., Blohmer J. U. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes // J Clin Oncol.– 2012.– V. 30.– I. 15.– P. 1796–1804.
3. Esserman L. J., Berry D. A., DeMichele A. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY1 TRIAL – CALGB150007/150012, ACRIN6657 // J Clin Oncol.– 2012.– V. 30.– I. 26.– P. 3242–3249.
4. Darb-Esfahani S.I., Loibl S., M ller B. M. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy // Breast Cancer Res.– 2009.– V. 11.– I. 5.– R69.
5. Rouzier R., Perou C. M., Symmans W. F. Breast cancer molecular subtypes respond differently to preoperative chemotherapy // Clin Cancer Res.– 2005.– V. 11.– I. 16.– P. 5678–5685.
6. Carey L. A., Dees E. C., Sawyer L. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes // Clin Cancer Res.– 2007.– V. 13.–– I. 8.– P. 2329–2334.
7. Wang S., Yang H., Tong F. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer // Gan To Kagaku Ryoho.– 2009.– V. 36.– I. 2.– P. 255–258.
8. Ring A. E., Smith I. E., Ashley S. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer // Br J Cancer.– 2004.– V. 91.– I. 12.– P. 2012–2017.
9. Guarneri V., Broglio K., Kau S. W. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors // J Clin Oncol.– 2006.– V. 24.– I. 7.– P. 1037–1044.
10. Rojas K. I. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer (TNBC) in a Peruvian institute // ASCO Meeting Abstracts.– 2013.– V. 31.– S. 15.– E12038.
11. Torrisi R., Balduzzi A., Ghisini R. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel // Cancer Chemother Pharmacol.– 2008.– V. 62.– I. 4.– P. 667–672.
12. Silver D. P., Richardson A. L., Eklund A. C. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer // J Clin Oncol.– 2010.– V. 28.– I. 7.– P. 1145–1153.
13. Byrski T., Huzarski T., Dent R. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res Treat.– 2014.– V. 147.– I. 2.–P. 401–405.
14. Frasci G., Comella P., Rinaldo M. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triplenegative large operable breast cancer // Ann Oncol.– 2009.– V. 20.– I. 7.– P. 1185–1192.
15. Yerushalmi R., Hayes M. M., Gelmon K. A. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers // Clin Breast Cancer.– 2009.– V. 9.– I. 3.– P. 166–172.
16. Allred D. C., Harvey J. M., Berardo M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis // Mod Pathol.– 1998.– V. 11.– I. 2.– P. 155–168.
17. Bloom H. J., Richardson W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years // Br J Cancer.– 1957.– V. 11.– I.– 3.– P. 359–377.
18. Chevallier B., Roche H., Olivier J. P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate // Am J Clin Oncol.– 1993.– V. 16.– I. 3.– P. 223–228.
19. Wang J., Shi M., Ling R. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial // Radiother Oncol.– 2011.– V. 100.– I. 2.– P. 200–204.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.